DiscoverMedical Industry Feature
Medical Industry Feature
Claim Ownership

Medical Industry Feature

Author: ReachMD

Subscribed: 35Played: 1,636
Share

Description

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.
493 Episodes
Reverse
Host: Zach Wallace, MD Guest: Anisha Dua, MD, MPH Guest: Frank Cortazar, MD Treatment decisions in ANCA-associated vasculitis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are often influenced by disease severity.1 However, theres no consensus definition of severe active GPA or MPA.2 Having a consistent framework matters because it gives clinicians a shared way to think about disease severity2 and identify patients who may require urgent evaluation, closer monitoring, and other treatment options3—while still leaving room for clinical judgement. Given that importance, Dr Zach Wallace speaks with Drs Anisha Dua and Frank Cortazar about a validated definition of severe active GPA and MPA and how it may be applicable in clinical practice. Dr Dua is the Director of the Northwestern Vasculitis Center and a Professor of Medicine in the Division of Rheumatology at Northwestern University Feinberg School of Medicine in Chicago, and Dr Cortazar is the Director of the New York Nephrology Vasculitis and Glomerular Center in Albany, New York. References: Chung SA, et al. Arthritis Rheumatol. 2021;73:1366–1383. Hellmich B, et al. Ann Rheum Dis. 2024;83:30–47. Chevet B, et al. Rheumatology (Oxford). 2023;62:1787–1803.
Guest: Gail J. Roboz, M.D. Gail J. Roboz, M.D., director of the Clinical and Translational Leukemia Program at NewYork-Presbyterian and Weill Cornell Medicine, discusses a recent clinical trial for acute myeloid leukemia (AML) that resulted in FDA approval of an all-oral treatment regimen for newly diagnosed older patients and those who cannot tolerate intensive chemotherapy. The trial established safety and efficacy by developing patient-tailored scheduling and dosing modifications to optimize outcomes. The new oral regimen improves convenience of care by eliminating the need for in-person infusions and is creating more opportunities for patients who may not have otherwise been candidates to undergo potentially curative stem cell transplantation.
Host: Vaidehi S. Dedania, MD Guest: Yewlin E. Chee, MD Guest: Joshua H. Uhr, MD Does phacovitrectomy improve outcomes over conventional PPV for rhegmatogenous retinal detachment repair in a phakic eyes? Or does it introduce unnecessary complexity? Vaidehi Dedania, MD; Yewlin Chee, MD; and Joshua Uhr, MD, review results from a multicenter cohort study published in Ophthalmology Retina and discuss whether the study's findings have any bearing on real-world decision-making, parse generational differences regarding perceived phacovitrectomy risks, and review whether changes to technology during the course of the study may have affected the findings.
Host: Maria Berrocal Guest: Dimitra Skondra, MD Could metformin reduce risk of wet AMD development? Maria Berrocal, MD, speaks with Dimitra Skondra, MD, PhD, about a study published in Ophthalmology Retina finding that metformin exposure was associated with up to 30% lower odds of new-onset wet AMD. They discuss what the findings mean for patients with and without diabetes, where the protective effect appears to break down, and what a prospective trial could tell us next.
Guest: Benjamin Lee, M.D. Guest: Jeffrey Port, M.D. Guest: Jonathan Villena-Vargas, M.D. Surgeons at NewYork-Presbyterian and Weill Cornell Medicine are advancing the use of single-port robotics for complex thoracic surgery. While multiport robotic surgery requires 4-5 incisions around the ribs, the single-port platform uses one incision through the diaphragm, improving surgery success and reducing recovery time. By being an early adopter, the center at NewYork-Presbyterian and Weill Cornell Medicine has become one of the highest volume single-port thoracic surgery programs in the U.S. The cardiothoracic team has successfully performed surgery for a range of thoracic malignancies, including late-stage lung cancer, mediastinal masses, and esophageal cancer. Their commitment to evolving robotic surgery and training the next generation is helping to expand access to minimally invasive thoracic procedures. © 2026 NewYork-Presbyterian
loading
Comments